KN-62 CaMKII Inhibition: Evidence & Use

KN-62 is described as a selective calcium/calmodulin-dependent protein kinase II inhibitor that binds the kinase calmodulin-binding site; the product information reports a Ki of 0.9 μM under the stated assay conditions. The same source identifies the compound as 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine with a molecular weight of 721.9 g/mol and formula C₃₈H₃₅N₅O₆S₂. In reported cellular studies, KN-62 inhibits insulin and cholecystokinin secretion and reduces stimulated glucose transport in skeletal muscle. A separate electrophysiology study shows why calcium-channel subtype controls matter: 1 μM v-agatoxin-IVA produced distinct effects in rat neurons carrying 5 mM Ba²⁺ currents, but that toxin study did not test KN-62.

Biological Rationale

CaMKII links calcium entry to downstream cellular responses. Calcium-bound calmodulin activates CaMKII. Activated CaMKII can then regulate processes such as secretion, metabolism, and cell-cycle signaling. A CaMKII inhibitor therefore provides a perturbation tool for testing whether a calcium-dependent response requires this kinase.

The calcium signal is not a single pharmacological entity. Neurons express multiple high-threshold voltage-gated calcium-channel classes. L-type channels are commonly distinguished by dihydropyridine sensitivity. N-type channels are commonly distinguished by ω-conotoxin GVIA sensitivity. P-type and Q-type channels show different sensitivity to ω-agatoxin-IVA. These distinctions are summarized in the Sidach and Mintz electrophysiology study.

The channel study recorded whole-cell currents from isolated rat subthalamic and sympathetic neurons. The recordings used 5 mM Ba²⁺ as the charge carrier. At 1 μM, v-agatoxin-IVA blocked multiple channel populations in subthalamic neurons. One population carried 50.4 ± 3.4% of the control current in five cells and showed high-affinity P-type-like pharmacology. A weaker-sensitive population contributed 14.0 ± 1.7% of the control current in five cells. These findings support careful channel-subtype controls, but they are not direct evidence for KN-62 activity.

Mechanism of Action of KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine

KN-62 is a small-molecule CaMKII inhibitor. The product description states that it acts by binding the calmodulin-binding site of CaMKII. This mechanism is distinct from direct blockade of every calcium-permeable channel. A reduction in a calcium-dependent endpoint after KN-62 treatment should therefore be interpreted as evidence consistent with CaMKII involvement, not automatically as proof that calcium entry itself stopped.

The reported CaMKII inhibition constant is Ki = 0.9 μM. The product page does not provide the complete buffer composition, pH, temperature, incubation time, enzyme concentration, or substrate concentration for that Ki measurement. Researchers should therefore treat 0.9 μM as a reported benchmark rather than a universal working concentration.

The dossier states that KN-62 does not affect other calmodulin-sensitive kinases in the described selectivity profile. Selectivity remains assay-dependent. It should be checked with matched enzyme controls, inactive-compound controls, vehicle controls, and pathway readouts that distinguish CaMKII inhibition from nonspecific cellular stress.

At the cellular level, the dossier associates KN-62 with regulated insulin and cholecystokinin secretion, skeletal-muscle glucose transport, and K562-cell proliferation. These observations connect the compound to calcium signaling, metabolism, secretion, and cell-cycle regulation. They do not establish that all effects arise from one identical pathway in every cell type.

Evidence & Benchmarks

• KN-62 is identified as 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine and is described as a selective CaMKII inhibitor that targets the calmodulin-binding site. Product information
• The reported CaMKII inhibition constant is Ki = 0.9 μM; the product page does not specify the full biochemical assay conditions for this value. Product information
• KN-62 is reported to inhibit regulated insulin and cholecystokinin secretion by blocking Ca²⁺ influx through L-type calcium channels in the described secretion assays. Product information
• KN-62 is reported to reduce insulin-stimulated glucose transport in skeletal muscle by approximately 46% under the stated insulin-stimulation assay conditions. Product information
• KN-62 is reported to reduce hypoxia-stimulated glucose transport in skeletal muscle by approximately 40% under the stated hypoxia-stimulation assay conditions. Product information
• In the described K562-cell studies, KN-62 inhibits cell growth in a dose-dependent manner and is associated with S-phase cell-cycle arrest and reduced CaMKII activity; no concentration or exposure time is specified in the product summary. Product information
• In isolated rat subthalamic neurons recorded with 5 mM Ba²⁺ as the charge carrier, 1 μM v-agatoxin-IVA targeted multiple calcium-channel populations. Sidach and Mintz, Journal of Neuroscience
• In sympathetic neurons, 1 μM v-agatoxin-IVA produced incomplete N-type calcium-current block of approximately 30% under the reported whole-cell recording conditions. This result concerns v-agatoxin-IVA rather than KN-62. Sidach and Mintz, Journal of Neuroscience
• The product is described as a solid with molecular weight 721.9 g/mol and chemical formula C₃₈H₃₅N₅O₆S₂. Product information

Applications, Limits & Misconceptions

Research applications

KN-62 can be used as a pathway perturbation tool in experiments that measure calcium-dependent secretion. Insulin secretion studies can pair compound exposure with calcium imaging, secreted-hormone measurement, and L-type-channel controls. Cholecystokinin experiments can use the same logic while preserving the specific secretory-cell model and stimulus.

In skeletal muscle, the reported insulin- and hypoxia-stimulated transport results support studies of CaMKII-linked metabolic regulation. A useful design measures basal transport, stimulated transport, vehicle response, and compound response in parallel. The two reported percentage reductions should not be treated as interchangeable because insulin stimulation and hypoxia represent different experimental conditions.

The K562 findings make KN-62 relevant to cell-cycle research. Flow cytometry or another validated DNA-content method can test the reported S-phase arrest. A CaMKII activity measurement can be collected in the same experiment. Growth suppression alone does not prove that CaMKII is the causal mediator.

Why this cross-domain matters, maturity, and limitations

Secretion, glucose transport, and K562 proliferation are different biological domains. The common link is that each can be tested with a CaMKII-directed perturbation, not that one universal mechanism has been demonstrated. The evidence is therefore strongest when KN-62 exposure is paired with pathway-specific readouts and orthogonal controls. The product summary supports these applications, while the cited neuronal channel study supplies pharmacological context rather than direct validation of the compound.

Common Pitfalls or Misconceptions

• Misconception: KN-62 is a universal calcium-channel blocker. The product description links some secretion effects to L-type calcium-channel influx, but KN-62 is described primarily as a CaMKII inhibitor. It should not be substituted for a channel-selective blocker without direct channel measurements.
• Misconception: the 0.9 μM Ki is a mandatory cellular dose. Ki is a biochemical potency parameter. Cellular exposure depends on assay design, compound availability, cell type, and endpoint timing.
• Misconception: every growth effect proves CaMKII dependence. K562 growth inhibition and S-phase arrest are reported associations. They require pathway controls before being assigned exclusively to CaMKII.
• Misconception: v-agatoxin-IVA data validate KN-62. The cited toxin study examined calcium-channel pharmacology in rat neurons. It did not measure KN-62, its Ki, or its cellular effects.
• Misconception: water is an acceptable preparation solvent. The product information describes KN-62 as insoluble in water. DMSO or ethanol preparation requires attention to solvent compatibility and the final vehicle percentage.

Workflow Integration & Parameters

APExBIO lists KN-62 as SKU A8180. The recommended workflow begins with a defined biological question, followed by a vehicle-matched dose series and a mechanistically relevant readout. The product page should be checked for current handling information before ordering or preparing solutions.

The related article KN-62: Precision CaMKII Inhibition for Advanced Cell Signaling emphasizes protocol design and troubleshooting. This article extends that discussion by separating vendor-reported product specifications from the independent calcium-channel study and by stating where evidence does not transfer across assay domains.

The related article KN-62 and the Calcium Logic of Memory discusses a hypothesis involving calcium/calmodulin signaling and memory maintenance. This article clarifies that the supplied evidence supports biochemical, secretion, metabolic, and K562-cell applications, not a demonstrated memory phenotype.

Protocol Parameters

• Identity check: Confirm the material as KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, SKU A8180, before use.
• Stock solvent: The product information reports solubility of at least 36.1 mg/mL in DMSO. Confirm complete dissolution and calculate the final vehicle percentage in the biological assay.
• Alternative solvent: The product information reports solubility of at least 15.88 mg/mL in ethanol with ultrasonic assistance. Validate ethanol tolerance in the selected cell system.
• Water: Do not plan an aqueous stock because the product information describes KN-62 as insoluble in water.
• Temperature: Store the solid desiccated at −20°C according to the product information. Minimize repeated warming and moisture exposure.
• Solution use: Use prepared solutions for short-term work only, as recommended by the product information. Record preparation date, solvent, concentration, and storage history.
• Shipping: Small-molecule shipments are specified for blue-ice conditions. Inspect the package and document receipt conditions before storage.
• Controls: Include vehicle-only, untreated, stimulated-only, and positive pathway controls. Add a viability or general-stress readout when interpreting growth or transport endpoints.
• Mechanistic readout: Pair the phenotype with CaMKII activity or a validated downstream readout. This workflow recommendation is not a replacement for the reported Ki assay.
• Channel attribution: Use direct calcium-current, calcium-imaging, or channel-selective control experiments before assigning an endpoint to L-type influx.

Conclusion & Outlook

KN-62 is a defined small-molecule tool for interrogating CaMKII-linked calcium signaling. The reported Ki of 0.9 μM, secretion findings, skeletal-muscle transport effects, and K562-cell observations provide distinct benchmarks rather than one universal assay result. The strongest experiments will preserve this distinction and report solvent, exposure, cell model, stimulation condition, and pathway readout.

The cited neuronal electrophysiology work reinforces a central limitation: calcium-channel pharmacology is heterogeneous, and a toxin result cannot be transferred automatically to a kinase inhibitor. Future work should therefore test CaMKII dependence and calcium-entry dependence as separate questions. That approach can clarify whether an observed phenotype reflects kinase inhibition, altered channel signaling, or both, without extending beyond the currently cited evidence.